Experimental combo aims to tame aggressive lymphoma without chemo
NCT ID NCT05495464
First seen Jun 25, 2026 · Last updated Aug 13, 2026 · Updated 3 times
Summary
This early-phase trial is testing a two-step approach for people with newly diagnosed, high-risk mantle cell lymphoma. First, patients receive a combination of acalabrutinib (a targeted drug) and rituximab (an antibody). Then, they get a one-time infusion of their own genetically modified immune cells (CAR T-cells). The goal is to see if this approach can control the cancer safely. Only 22 participants will be enrolled at a single center.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Acalabrutinib, rituximab, and brexucabtagene autoleucel (CAR T-cell therapy)
- What this could lead to
- If successful, this combination could offer a new treatment option for people with high-risk mantle cell lymphoma, potentially improving disease control without needing long-term chemotherapy.
- What could go wrong
- This is a very early (Phase 1) pilot study with only 22 participants. The treatment may cause serious side effects, and it is not yet known if it will work better than standard therapies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- Can engineered immune cells tackle brain lymphoma?
- Talking about the end: could guided conversations reduce futile cancer treatments?